Literature DB >> 15956528

Anti-tumor necrosis factor alpha-associated multiple sclerosis.

David S Titelbaum1, Alexandra Degenhardt, R Philip Kinkel.   

Abstract

A case of multiple sclerosis presenting during anti-tumor necrosis factor treatment for rheumatoid arthritis is discussed. This association has been reported in the nonradiological literature, but is an important association for radiologists to be aware of, as they may be in a position to first suggest the diagnosis.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15956528      PMCID： PMC8149094     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


  10 in total

Review 1.  Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

Authors:  W H Robinson; M C Genovese; L W Moreland
Journal:  Arthritis Rheum       Date:  2001-09

2.  Retrobulbar optic neuritis associated with infliximab.

Authors:  Rod Foroozan; Lawrence M Buono; Robert C Sergott; Peter J Savino
Journal:  Arch Ophthalmol       Date:  2002-07

3.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

4.  Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

Authors:  B W van Oosten; F Barkhof; L Truyen; J B Boringa; F W Bertelsmann; B M von Blomberg; J N Woody; H P Hartung; C H Polman
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

5.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

Authors:  L W Moreland; S W Baumgartner; M H Schiff; E A Tindall; R M Fleischmann; A L Weaver; R E Ettlinger; S Cohen; W J Koopman; K Mohler; M B Widmer; C M Blosch
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

6.  Onset of multiple sclerosis associated with anti-TNF therapy.

Authors:  N L Sicotte; R R Voskuhl
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

Review 7.  Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system.

Authors:  K W Selmaj
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

8.  TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

Authors: 
Journal:  Neurology       Date:  1999-08-11       Impact factor: 9.910

9.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

10.  Quantitative cerebral MR in rheumatoid arthritis.

Authors:  S I Bekkelund; C Pierre-Jerome; G Husby; S I Mellgren
Journal:  AJNR Am J Neuroradiol       Date:  1995-04       Impact factor: 3.825
  10 in total
  25 in total

Review 1.  Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system.

Authors:  Sara L Montgomery; William J Bowers
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

2.  TNFR2 limits proinflammatory astrocyte functions during EAE induced by pathogenic DR2b-restricted T cells.

Authors:  Itay Raphael; Francisco Gomez-Rivera; Rebecca A Raphael; Rachel R Robinson; Saisha Nalawade; Thomas G Forsthuber
Journal:  JCI Insight       Date:  2019-12-19

3.  A dendrimer-based immunosensor for improved capture and detection of tumor necrosis factor-α cytokine.

Authors:  Admira Bosnjakovic; Manoj K Mishra; Hye Jung Han; Roberto Romero; Rangaramanujam M Kannan
Journal:  Anal Chim Acta       Date:  2012-01-18       Impact factor: 6.558

Review 4.  New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.

Authors:  Takumi Matsumoto; Ichiro Nakamura; Ayumi Miura; Gen Momoyama; Katsumi Ito
Journal:  Clin Rheumatol       Date:  2012-11-14       Impact factor: 2.980

Review 5.  Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy-related intracranial effects.

Authors:  Christie M Lincoln; Peter Fata; Susan Sotardi; Michael Pohlen; Tomas Uribe; Jacqueline A Bello
Journal:  Br J Radiol       Date:  2017-11-03       Impact factor: 3.039

Review 6.  Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping.

Authors:  Ippazio Cosimo Antonazzo; Emanuel Raschi; Luca Vignatelli; Elisa Baldin; Trond Riise; Roberto D'Alessandro; Fabrizio De Ponti; Elisabetta Poluzzi
Journal:  Drug Saf       Date:  2017-09       Impact factor: 5.606

Review 7.  Neurological disorders and inflammatory bowel diseases.

Authors:  Giovanni Casella; Gian Eugenio Tontini; Gabrio Bassotti; Luca Pastorelli; Vincenzo Villanacci; Luisa Spina; Vittorio Baldini; Maurizio Vecchi
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

8.  Multiple sclerosis during adalimumab treatment in a case with ankylosing spondylitis.

Authors:  Uğur Uygunoğlu; Derya Uluduz; Koray Taşçılar; Sabahattin Saip
Journal:  Rheumatol Int       Date:  2012-12-27       Impact factor: 2.631

9.  Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy.

Authors:  Alexander Winkelmann; Robert Patejdl; Sabine Wagner; Reiner Benecke; Uwe Klaus Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

10.  Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.

Authors:  E Andreadou; E Kemanetzoglou; Ch Brokalaki; M E Evangelopoulos; C Kilidireas; A Rombos; E Stamboulis
Journal:  Case Rep Neurol Med       Date:  2013-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.